Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 Apr 12. pii: e8446. doi: 10.15252/emmm.201708446. [Epub ahead of print]

2.

Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.

Báez-Vega PM, Echevarría Vargas IM, Valiyeva F, Encarnación-Rosado J, Roman A, Flores J, Marcos-Martínez MJ, Vivas-Mejía PE.

Oncotarget. 2016 Jun 14;7(24):36321-36337. doi: 10.18632/oncotarget.9216.

3.

Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE.

Mol Cancer Ther. 2015 Oct;14(10):2260-9. doi: 10.1158/1535-7163.MCT-14-0801. Epub 2015 Jul 30.

4.

Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.

Echevarría-Vargas IM, Valiyeva F, Vivas-Mejía PE.

PLoS One. 2014 May 27;9(5):e97094. doi: 10.1371/journal.pone.0097094. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e116447.

Supplemental Content

Loading ...
Support Center